Deal Library / Pharma BD Deal Intelligence

GSK plc — Pharma Deals

The Pharma Closeout tracks 22 deals, $82.2B in disclosed deal value, 17 with a post-close Outcome Score for GSK plc.

Median Critic Score: 75  ·  Median Outcome Score: 66

Best outcome: GSK plc / SmithKline Beecham (79)  ·  Weakest outcome: GSK plc / Merck KGaA (29)

All 22 deals

• GSK plc / SmithKline Beecham — 2000 · $12.0B · Worked — the deal delivered on its rationale.
• GSK plc / Pfizer Inc. — 2018 · $0.0M · Worked — the deal delivered on its rationale.
• GSK plc / Novartis AG — 2014 · $16.0B · Worked — the deal delivered on its rationale.
• GSK plc / Hansoh Pharmaceutical Group Co. Ltd. — 2023 · $1.7B · Largely worked — most objectives met.
• GSK plc / Nuvalent, Inc. — 2026 · $10.6B · Largely worked — most objectives met.
• GSK plc / Sierra Oncology Inc. — 2022 · $1.9B · Largely worked — most objectives met.
• GSK plc / Human Genome Sciences — 2012 · $3.6B · Largely worked — most objectives met.
• GSK plc / Bellus Health Inc. — 2003 · $2.0B · Largely worked — most objectives met.
• GSK plc / IDRx Inc. — 2025 · $1.1B · Largely worked — most objectives met.
• GSK plc / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2025 · $12.0B · Largely worked — most objectives met.
• GSK plc / Stiefel Laboratories — 2009 · $3.6B · Largely worked — most objectives met.
• GSK plc / Duality Biologics (Suzhou) Co. Ltd. — 2024 · $975M · Largely worked — most objectives met.
• GSK plc / Aiolos Bio — 2024 · $1.0B · Largely worked — most objectives met.
• GSK plc / Suzhou Siran Biotechnology Co., Ltd. — 2026 · $1.1B · Mixed — partial payoff, real shortfalls.
• GSK plc / Affinivax Inc. — 2022 · $3.3B · Mixed — partial payoff, real shortfalls.
• GSK plc / 23andMe, Inc. — 2018 · $300M · Underwhelmed — fell short of the thesis.
• GSK plc / Merck KGaA — 2019 · $4.2B · Did not work — the deal failed to deliver.
• GSK plc / Boston Pharmaceuticals Inc. — 2025 · $2.0B
• GSK plc / CureVac N.V. — 2024 · $1.6B
• GSK plc / SCYNEXIS, Inc. — 2023 · $593M
• GSK plc / Bellus Health Inc. — 2023 · $2.0B
• GSK plc / Spero Therapeutics, Inc. — 2022 · $600M

← Deal Library  ·  Interactive search  ·  How we score deals